Medicine

Semaglutide's effects on fatty liver disease and liver inflammation linked to metabolism: Review and analysis of placebo-controlled trials

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Semaglutide is being evaluated for potential disease-modifying effects in nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH).

  • NAFLD and NASH are significant causes of chronic liver disease globally.
  • There are currently no approved medications for treating NAFLD or NASH.
  • Semaglutide is known for its metabolic and weight-loss benefits.
  • The study explores the possible impact of semaglutide on liver disease progression.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

No funding or competing interests reported.
PubMed

Related papers

Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 30 papers
systematic review
Oct '25
Semaglutide treatment for adults with obesity
cited by 6 papers
systematic review
Jun '25
Silymarin use in adults with fatty liver disease linked to metabolism problems
cited by 1 paper
systematic review
Oct '24
Vitamin E use in people with non-alcoholic fatty liver disease
cited by 7 papers
systematic review
Mar '24
GLP-1 receptor agonists and their impact on liver scarring and inflammation in fatty liver disease and fatty liver inflammation
top 30% journal
cited by 26 papers
systematic review
Apr '26
THR-β Agonists Compared to Incretin Treatments for Early Metabolic Liver Disease Confirmed by Biopsy
journal article
Dec '24
Comparing two diabetes drug types for treating metabolic fatty liver disease and liver inflammation
top 20% journal
cited by 11 papers
systematic review
Jun '25
Effectiveness of GLP-1 Treatments for Fatty Liver Disease Linked to Metabolic Problems and Its Inflammatory Form
top 5% journal
cited by 36 papers
systematic review
Jun '26
Long-term effects of weight-loss drugs in people with high blood pressure
systematic review

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief